time, following which the growing tumor is excised. This method of isoimmunization precludes prolonged courses of immunization in attempts to increase the levels of immunity produced, unless repeated implantation and excision cycles are employed. In addition, this method for the induction of tumor immunity in animals cannot readily be applied as a possible model for the induction of a similar immunity in human can cer patients. It therefore seemed appropriate to investigate the immunogenicity of cell-free extracts of such chemically in duced tumors in a syngeneic murine system.
The studies to be reported here were undertaken (a) to at tempt the â€oehyperinimunizationâ€•of inbred mice against a syngeneic tumor, (b) to develop in experimental animals tech nics of immunization which might â€¢ serve as models for sub sequent attempts at the immunotherapy of human cancer, and (c) to attempt to extract and, if possible, to concentrate speci fic tumor antigens from tumor tissue in order to isolate an immunogenically active vaccine.
Numerous investigators have demonstrated the presence of specific tumor antigens in tumor extracts of various types. To enumerate all of these studies is beyond the scope of this paper, and the reader is referred to the reviews by Zilber (21), Milgrom (1 1), and Southam (19) which discuss this subject in detail and review the related literature. However, certain re cent work in the area is noteworthy. In 1959, Taylor et a!. (20) demonstrated the presence of tumor-specific antigens in fluorocarbon-treated cell-free extracts of neoplastic tissue of fowl and man. The following year, De Carvalho (4) reported the isolation of tumor-specific antigens from human tumors and leukemic cells by a different type of extraction with fluorocarbon. In the same year, Aizawa and Southam (1) re ported the detection of circulating antitumor antibodies to homotransplanted human cancer cells in cancer patients, em ploying as an antigenic material a crude saline extract of these cells. In 1962, McKenna et a!. (10) reported the extraction of distinctive antigens from HeLa and J 111 cells by a fluoro carbon extraction technic similar to that of Taylor. Blakemore and McKenna (2) were able to detect antibodies reactive with these antigenic extracts in 43 percent of 257 patients with cancer. In the studies to be reported here, the immunogenicity and antigenicity of three types of cell-free extracts of neo plastic tissues were investigated in an isologous munne system. The three extracts employed resemble generally the saline ex tract of Aizawa and Southam, the fluorocarbon-treated ex tracts of Blakemore, McKenna, and Taylor, and the fluoro carbon extract of De Carvalho.
SUMMARY
The induction of antitumor isoimmunity to an ethiodol induced fibrosarcoma in female BALB/c mice and to a methyl cholanthrene-induced fibrosarcoma (MC 1) in female C3H/ HeN mice was accomplished using three different cell-free ex tracts of tumor tissue, a saline extract and two different fluorocarbon-treated extracts. The degree of immunity ob served was dependent upon the length and intensiveness of the course of immunization, the route of immunization, and the size of the challenge tumor-cell inoculum. The presence of a circulating antibody of low titer was detected in immunized animals exhibiting significant tumor immunity. This antibody was not demonstrable in control animals or in immunized ani mals in which no significant immunity was observed. Animals INTRODUCTION Chemically induced sarcomas have been shown to be anti genic and immunogenic in syngeneic hosts. It has been estab lished that the immunity observed in these systems is due to specific antigenic properties of the tumors and not to minor histocompatibiity differences among the inbred animals used. Recent reviews by Old and Boyse (12), Hirsch (7), and Hattler and Amos (6) provide detailed analyses of the abundant litera ture in this field.
With the exception of Klein (8) and Revesz (17) , who im munized animals with heavily irradiated tumor cells, tumor isoimmunity in these systems has always been induced by al lowing a chemically induced tumor to grow for a period of
MATERIALS AND METHODS

Tumor, Mice, and Preparation of Cell Suspensions
The tumor used in the studies involving BALB/c mice was a fibrosarcoma which arose subcutaneously in a female BALB/c mouse following the local injection of ethiodol (iodinated poppy seed oil). It was in its first transplant generation at the start of the study, being carried in the hind limbs of syngeneic mice. The tumor used for immunization of the C3H/HeN mice was a fibrosarcoma (MC 1) induced by 20-methylcholanthrene in the hind limb of a female C3H/HeN mouse. It was in its first transplant generation at the start of the study. The second tumor used for comparative purposes was an adenocarcinoma of the breast (Sp 1) which arose spontaneously in a female C3H/HeN mouse. It was also in its first transplant generation at the start of the study. Female BALB/c and C3H/HeN mice obtained from the NIH animal colony were fed Purina Labora tory chow and water ad libitum, and housed in groups of 30 in large plastic cages. Tumor-cell suspensions were prepared as follows: A tumor-bearing animal was killed by cervical disloca tion and the tumor was minced with scissors in a sterile Petri dish. The tumor tissue was then suspended in cold sterile Hank's balanced salt solution without antibiotics and passed through a Snell cytosieve (18) . The cells were counted in a hemocytometer and cell viability determined by the dye ex clusion technic using 0.5 percent trypan blue.
Preparation of Cell-free Extracts
All three extracts were prepared sequentially from the same sample of tumor tissue. All operations were performed at or very near 0Â°C. Tumor tissue was excised aseptically from tumor-bearing animals and necrotic tissue was removed. The tissue was weighed and then homogenized in 5 volumes of phosphate-buffered saline (PBS) pH 7.2 at high speed in a Virtis 45 homogenizer for 10 minutes. The homogenate was centrifuged at 3,000 X g for 15 minutes, following which the supernate was saved and the sediment homogenized in 3 vol umes of PBS for 10 minutes at high speed. Following centrifu gation at 3,000 X g for 15 minutes, the sediment was dis carded and the supernate combined with that of the first cen trifuged at 7,000 X g for 20â€"30minutes. The sediment was then discarded and the supernate constituted the â€oesaline tu mor extract.â€• A portion of this extract was then homogenized with Â½ vol ume of the fluorocarbon Genetron 113 (trifluorotrichloro ethane), Allied Chemical Co., New York, N.Y., for 1 minute at high speed and then centrifuged at 3,000 X g for 10 minutes. This produced a solid protein gel, a clear supernatant phase and, sometimes, a small third phase of free Genetron below the protein gel. The protein gel was saved and the supernate homogenized with an additional Â½ volume of Genetron. This extraction procedure was repeated until, following centrifuga tion, no additional protein gel was obtained and only 2 phases, clear supernate and free Genetron, appeared. Five or six ex tractions were usually required. The free Genetron was then discarded and the supernate constituted the â€oeGenetronsuper nate.â€• All the protein gels were then combined and stirred vigor ously, expressing free Genetron, which was decanted and dis carded. A volume of 0.15 M phosphate buffer pH 7.2 equal to the original volume of PBS was then added and mixed vigor ously with the protein gel. The mixture was then centrifuged for 10â€"15minutes at 1100 X g following which three phases again appeared. The supernatant was decanted and saved, after which the free Genetron was decanted and discarded. More free Genetron was then expressed by vigorous stirring and de canted. The same supernate of 0.1 5 M phosphate buffer was replaced and mixed vigorously. The entire process was then repeated, replacing the same buffer solution each time until free Genetron could no longer be expressed. Often 15â€"20 extractions were required. The remaining gel was then dis carded and the supernate constituted the â€oeGenetronextract.â€•
The protein concentrations of all extracts were determined by the method of Lowry et a!. (9) . The extracts were stored at â€"87Â°C and defrosted immediately prior to use.
Immunization of Animals
Ethiodol-induced Fibrosarcoma in BALB/c Mice. The initial experiment consisted of 4 groups of 30 six-week-old female BALB/c mice. Three groups were given one of the three ex tracts, either the saline tumor extract, the Genetron supernate, or the Genetron extract. Each extract was diluted to contain 0.5 mg of protein in each 0.25 ml and emulsified with an equal volume of complete Freund's adjuvant. Each animal received 0.5 ml of this mixture subcutaneously. A control group of 30 mice received 0.5 ml of Freund's adjuvant emulsified with an equal volume of saline. Ten days later, each animal received 0.25 ml of extract containing 0.5 mg of protein without Freund's adjuvant, and the control group received 0.25 ml of saline only. Two weeks later all animals were inoculated intra muscularly with 30,000 viable tumor cells from the second transplant generation of the same ethiodol-induced fibrosar coma. At this time 30 additional stock mice were inoculated with the same tumor-cell suspension to serve as challenge con trols.
In the second and more elaborate experiment, groups of 60 six-week-old female BALB/c mice were given a course of 6 weekly injections, either subcutaneously or intraperitoneally, or 0.25 ml of one of three extracts of the second transplant generation of the fibrosarcoma. Each extract was diluted to contain 0.5 mg of protein in 0.25 ml. Three of these injections included an equal volume of complete Freund's adjuvant for a total volume of 0.5 ml. Control groups of mice were injected with Freund's adjuvant and normal saline according to the same schedule. The mice immunized subcutaneously received adjuvant with the first three injections, while those inoculated intraperitoneally received adjuvant with Doses 1, 3 , and 5. This was necessary because we had previously noted that re peated intraperitoneal injections of Freund's adjuvant at brief intervals resulted in a high mortality in these mice. Six weeks after the last injection, half the animals in each group were inoculated intramuscularly with 10,000 viable tumor cells, and the remaining mice in each group were given 1,000 viable tu mor cells. At this time four additional groups of 30 stock mice were given challenge doses and served as challenge controls. All
YosefH. Pikh 1: 10,000. The pooled plasma was then stored at â€"87Â°C. Anti body titers were determined by a modification of the tanned red cell hemagglutination method of Boyden (3), described in a previous paper (14) . The antigen used to sensitize the tanned red cells was the saJine tumor extract, since it is a slight moth fication of the antigen used by Aizawa and Southam (1) to detect antitumor antibodies in human patients by the same hemagglutination method of Boyden used in this study. Two antigen dilutions were used, one containing 1.5 mg and the other 3.125 mg of protein per ml of tanned cells to be sensi tized. All titrations of mouse plasma were performed in dupli cate using cells sensitized with each of these antigen concentra tions. These two antigen concentrations were selected since previous studies in our laboratory (14) had shown these two antigen concentrations to be optimal for use in this particular assay system.
RESULTS
Initial Experiments in BALB/c Mice: Two Injections of Extract
The results of this experiment are graphically presented in Charts 1 and 2. There was no significant difference between 0 animals in which tumors did not develop were challenged three months later with 1,000 viable cells from the first transplant generation of a second ethiodol-mduced fibrosarcoma which arose in another female BALB/c mouse. In a control experi ment, groups of 30 mice were immunized subcutaneously, in an identical fashion, with one of three cell-free extracts of a pool of normal BALB/c tissues. This normal tissue pool in cluded skin, skeletal muscle, heart, lung, liver, kidney, spleen, adrenal, uterus, and ovary, and was obtained from 15 normal 6-week-old mice. In these last two experiments, 30 stock mice were inoculated with each challenge inoculum to serve as chal lenge controls.
Methyicholanthrene-induced Fibrosarcoma in @3H/HeN Mice. Groups of 60 six-week-old female C3H/HeN mice were given a course of 6 weekly injections, either subcutaneously or intraperitoneally, of 0.25 ml of one of the three cell-free ex tracts of the fibrosarcoma (MC 1), diluted to contain 0.5 mg of protein. Three injections included an equal volume of com plete Freund's adjuvant for a total volume of 0.5 ml. In the groups immunized subcutaneously, the adjuvant was given in the first three injections, while, in the groups inoculated intra peritoneally, the adjuvant was included in Injections I , 3, and 5. Control groups of 60 mice were injected with Freund's adjuvant and normal saline according to the same schedules. Additional groups of 30 mice were immunized subcutaneously in an identical fashion with one of three cell-free extracts of a pool of normal C3H/HeN tissues. This normal tissue pool in cluded skin, skeletal muscle, heart, lung, liver, kidney, spleen, adrenal, uterus, and ovary, and was obtained from 15 normal 6-week-old female C3H/HeN mice.
Six weeks following the last injection, half the animals in each group of 60 mice immunized with the MC 1 sarcoma extracts were challenged intramuscularly with 1,000 viable MC 1 tumor cells. The remaining mice in each group were inocu lated with 1,000 viable Sp 1 tumor cells. At this time control groups of 30 stock mice were inoculated with each cell suspen sion to serve as challenge controls. The 1,000-cell challenge inoculum was selected, since previous studies in our laboratory had shown it to be that dose which produced just under 100 percent tumor takes in untreated animals. Three to five days prior to challenge each animal was bled from the ophthalmic venous plexus for antibody studies. All animals in which tu mors did not develop were rechallenged 4Â½months later with 1,000 viable MC 1 tumor cells. These mice were bled for anti body studies 3â€"5days prior to rechallenge. Again a group of 30 challenge control mice were injected with this cell suspen sion.
The groups of 30 mice which had been immunized with the extracts of normal C3H/HeN tissue were all challenged with 1,000 MC 1 tumor cells six weeks after the last injection of extract.
Antibody Titrations
Three to five days prior to challenge, all mice were bled from the ophthalmic venous plexus into heparinized capillary pi pets. Blood from mice in each experimental group was pooled and centrifuged at 1500 X g. The plasma was removed and merthiolate (thimerosal) added to a fmal concentration of Murine Sarcoma Immunogenicity groups in the total percentage of animals developing tumors.
However, the mice receiving the saline tumor extract exhibited a significant prolongation of the latency period. At any given time interval, the tumors in this group had a smaller mean tumor diameter. In addition, the animals in this group survived for a longer period of time. When the results at 3 weeks after challenge are presented in tabular form, these differences be come apparent (Table 1) .
On the basis of these results it became clear that some degree of immunity was present but that it was quantitatively small. Table 1 What could be done to enhance it? (a) A more prolonged and vigorous course of immunization could be used. (b) A dif ferent route of immunization might be tried. (c) Smaller chal lenge inocula might serve to demonstrate smaller degrees of immunity. The smallest challenge inoculum used ought to be that which produced just under 100 percent tumor takes in control animals. All of these points were included in the design of the second experiment.
Second Experiment in BALB/c Mice: Six Weekly
Injections of Extract
The results of this experiment are illustrated in Charts 3â€"6, and the numerical values for total tumor takes at the end of the study are tabulated in Table 2 . Now several facts became obvious. When a more intensive and prolonged course of ito munization was used, all the extracts were, to some extent, immunogenically active. The subcutaneous route of immuniza tion was definitely superior to the intraperitoneal route. The Genetron supernate fraction appeared to be the most potent fraction immunogenically, reducing the total percent tumor development by over one third when administered subcutane ously and when a lO@cell challenge inoculum was used. YosefH. Filch Table 2 Tumor growth in BALB/c mice immunized for 6 weeks with cell-free extracts of the chemically induced fibrosarcoma and challenged 6 weeks later. Final results. were obtained. In this table only the groups immunized sub cutaneously and then challenged with l0@ cells of the immuni zing tumor are included, since in the other groups, the number of mice surviving was too small for results to be considered When immunized mice in which tumors did not develop fol lowing initial challenge with 1,000 tumor cells were challenged three months later with 1,000 viable cells from a second ethio dol-induced fibrosarcoma, the results tabulated in Table 3 ofmice with tumors Murine Sarcoma Immunogenicity reliable. No cross-reactivity between the two fibrosarcomas was observed, since mice resistant to a challenge of 10@cells from the tumor used for immunization did not evidence any increase in resistance to a challenge of 10@tumor cells from a second ethiodol-induced fibrosarcoma which arose in a differ ent syngeneic mouse. Table 4 shows the results obtained wI@enBALB/c mice were immunized with cell-free extracts of normal syngeneic mouse tissues. These results indicate that immunization with extracts of normal tissues did not affect the susceptibility of these animals to subsequent challenge with tumor cells. Table 4   Table 3 Total tumor takes in BALB/c mice immunized with cell-free extracts of normal syngeneic mouse tissues and challenged with 103 tumor cells.
PERCENT TUMOR TAKES
SUBCUTANEOUSIMMUNIZATION
IO@ CHALLENGE DOSE
The results of the antibody titrations on the plasma of the immunized animals and control groups are given in Table 5 . The percentage of tumor takes following the l0@ cell challenge inoculum is presented beside the antibody titers for each group. Plasma from all four challenge control groups and from both adjuvant and saline only groups were completely unreac tive. The plasma from the group of mice immunized subcuta neously with the saline extract was positive to a titer of 1:5 (2 tubes). Plasma from the group immunized subcutaneously with the Genetron supernate fraction also gave a 1:5 titer, and plasma from the group immunized subcutaneously with the Genetron extract fraction reacted positively at 1:2.5 (1 tube) and equivocally at 1:5. None of the groups immunized intra peritoneally provided a positive titer. a@ new group of 30 stock animals serving as a control for the challenge inoculum from the second fibrosarcoma. Table 5 Cl)
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Antitumor antibody titers in female BALB/c mice immunized with cell free extracts of a chemically induced fibrosarcoma.
Experiments in C3H/HeN Mice
The results of the active immunization of C3H/HeN with the cell-free extracts of the MC 1 tumor are ifiustrated in Charts 7â€"10, and the numerical values for total tumor takes in all groups are compiled in Table 6 . It can be seen that a marked degree of immunity was produced. This immunity was most striking in the groups immunized with the saline extract and with the Genetron extract fractions, although moderate im munity was observed in mice receiving the Genetron supernate YosefH. Filch fraction subcutaneously. The subcutaneous route of immuni-difference between the two is not statistically significant. zation proved to be much more effective than the intraperi-When animals immunized against extracts of the MC 1 tumor toneal route. Although the percentage of tumor takes in ani-were challenged with Sp 1 tumor cells, no immunity to the Sp mals immunized with the Genetron extract is slightly lower 1 tumor was noted in any group regardless of the degree of than that observed in mice receiving the saline extract, the immunity evidenced by the group to the MC 1 tumor. 
-
:â€˜-â€˜a--â€". Table 8 . It is obvious that immunization with extracts of normal tissues did not in any way influence the response of these animals to a subsequent inoculation with tumor cells. Table 9 presents the antibody titers and total tumor takes observed when those mice who failed to develop tumors after initial challenge with MC 1 were rechallenged 4Â½months later with 1,000 viable MC 1 tumor cells. The circulating antibodies were still present, but their titers are now one-half as large. (100.0%)00
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YosefH. Filch Table 9 Total tumor takes and antitumor antibody titers in C3H/HeN mice immune to methylcholanthrene-induced ed fibrosarcoma (MC 1) on initial challenge and rechallenged after 4.5 months with iO@MC 1 tumor cells.
Moreover, active immunity to the MC 1 tumor persisted in all groups in which immunity had initially been produced. The degree of immunity observed for each group was almost un changed after 4Â½months, except for the group of mice im munized subcutaneously with the Genetron extract. In this group only 11.8 percent tumor takes had been noted at the time of original challenge, whereas 40 percent of the animals rechallenged after 4Â½months developed tumors.
DISCUSSION
The results of these studies suggest an active immunization to specific tumor antigens contained in cell-free extracts of tumor tissue resulting in increased host resistance to sub sequent syngeneic tumor transplants. The subcutaneous route of immunization was clearly observed to be preferable to the intraperitoneal route. The degree of immunity produced was related to the length and intensiveness of the course of im munization. The immunity observed was dependent on the size of the challenge inoculum used. The observation that im munization with cell-free extracts of normal syngeneic mouse tissues failed to provide protection against subsequent tumor cell inoculation indicates the tumor specificity of the antigens contained in the extracts. The immunity observed was, there fore, shown not to be due to minor genetic disparities or to differences in minor transplantation antigens between mem bers of this inbred strain of mice. The immunity produced appeared to be specific for the immunizing tumor, since BALB/c mice resistant to transplants of the immunizing ethio dol-induced tumor evidence unaltered sensitivity to transplants from a second ethiodol-induced fibrosarcoma which arose in another syngeneic mouse.
Several comparisons of the two tumor-host systems studied can be made. Extracts of the MC 1 tumor in C3H/HeN mice were immuno genically and antigenically considerably more active than were the extracts of the ethiodol-induced sarcoma in BALB/c mice. Since it is known that different chemically induced tumors may vary greatly in their antigenicity (5, 13, 15) , it is likely that the MC 1 tumor was more antigenic than was the ethio dol-induced sarcoma. (c) In both the C3H/HeN and the BALB/c studies, the saline extract was consistently active im munogenically and antigenically. This is to be expected since it presumably contains all or most of the antigens extractable from the tumor. (d) However, in the BALB/c experiments, the greater portion of this activity seemed to be extracted into the Genetron supernate fraction when the saline extract was treated with fluorocarbon, whereas in the C3H/HeN studies, the majority of the activity seemed to be extracted into the Genetron extract fraction. A possible explanation for this dis parity is that the tumor antigens of the two tumors may be chemically different so that, in the one tumor system they are extracted preferentially into the Genetron supernate, and in the other, they are extracted into the Genetron extract frac tion. A second possibility is as follows: There are at least two tumor-specific antigens in each tumor, but no major chemical differences exist between comparable antigens of each tumor. At least one antigen from each tumor is extracted into each of the fluorocarbon-treated extracts. However, in the MC 1 tu mor, the antigen or antigens extracted into the Genetron cx tract fraction are the more active antigenically and immuno genically, while in the ethiodol-induced sarcoma the more active antigen or antigens are those extracted into the Gene tron supernate. (e) In both tumor-host systems the antigeni city of each particular extract, asjudged by its ability to evoke the production of isoantibody, parallels its immunogenicity, as measured by its ability to produce an increase in the resistance of immunized animals to subsequent inoculation with viable This is within the range of titers obtained by Aizawa and Southam (1) when, by essentially the same method as that used in the present study, they measured circulating antibodies to homotransplanted human cancer cells. In the present study, the presence of these isoantibodies and the magnitude of their titers correlates with the presence and degree of antitumor isoimmunity observed in the various experimental groups. The tumor specificity of these antibodies has not been conclusively demonstrated. The possibility exists that these antibodies may be directed against altered normal tissue antigens and/or de natured proteins, rather than to specific tumor antigens. How ever, plasmas obtained from C3H/HeN mice immunized with extracts from the MC 1 tumor, which exhibited positive titers when reacted with sheep red cells sensitized with antigen pre pared from the MC 1 tumor, failed to react with red cells sensitized with antigen prepared from the Sp 1 tumor. If these antibodies were largely directed against denatured proteins and/or altered normal tissue antigens, one might have expected plasmas, reactive against one C3H/HeN tumor, to cross-react at least partially with a second C3H/HeN tumor. Moreover, as suming these antibodies to be directed against tumor-specific antigens, it cannot be stated whether these antibodies play an important role in mediating the immunity observed. They may share a causal role with nonhumeral cell-associated mecha nisms, or they may be an incidental finding in a situation in which all or most of the immunity demonstrated is dependent upon cell-associated mechanisms. The immunity produced in the C3H/HeN mice has been shown to be of at least 4Â½months duration. The level of immunity in each experimental group did not appear to fall appreciably during this time interval except in the case of the group immunized subcutaneously with the Genetron extract fraction. The immunity in this group decreased by a factor of 4 during thisperiod. Likewise, circulating antibodies have been shown to persist for a similar period of time, although, after 4Â½months, the titers had fallen to one-half their original levels.
The immunity induced by these extracts has been shown to be tumor specific. When mice were immunized against cell-free extracts of pooled normal C3H/HeN tissues, no resistance to subsequent tumor-cell transplants could be produced. This rules out the possibility that these extracts were effective in increasing host resistance to subsequent tumor transplants by virtue of a nonspecific stimulation of the host's reticuloendo thelial system. More important, it confirms the fact that the immunity produced is related to tumor antigens specifically and is not due to persistent minor genetic disparities between individual mice within the inbred strain.
Although BALB/c mice immunized with extracts of an ethiodol-induced sarcoma failed to evidence increased resist ance to challenge with a second ethiodol-induced sarcoma and, although C3H/HeN mice immunized with extracts of the MC I tumor evidenced no increase in their resistance to transplants of the Sp 1 tumor regardless of the degree of their immunity to MC 1, the possibility that the immunity produced and/or the antibodies detected might cross-react with other chemi cally induced tumors within the same inbred mouse strains has not been ruled out. In a recent paper, Reiner and Southam (16) have suggested that tumor-specific antigenic alterations may be shared by some, but not all, tumors of the same eti ology, i.e., induced in an inbred mouse strain at the same time by the same carcinogen. Since no search was made on circulat ing antibodies in their study, one cannot know whether such antibodies (if present) would likewise react with some, but not all, of the tumors.
